PSA

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

Annual PSA Screening Best for Reducing Prostate Cancer Deaths

By

A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

By

Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.

PSA Level 3 Months After Radiation Tx May Predict Outcome

PSA Level 3 Months After Radiation Tx May Predict Outcome

Findings for men with intermediate- and high-risk prostate cancer.

Novel Blood Test Improves Detection of High-Grade Prostate Cancer

Novel Blood Test Improves Detection of High-Grade Prostate Cancer

By

IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.

Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed

Optimal Post-Radical Prostatectomy Follow-up Schedule Proposed

By

Investigators suggest PSA testing frequencies based on post-operative baseline PSA.

Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis

Gleason 4+3 vs 3+4 PCa Tied To Higher Risk of Metastasis at Diagnosis

By

Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.

Single PSA Screening Has No Effect on Prostate Cancer Mortality

Single PSA Screening Has No Effect on Prostate Cancer Mortality

By

Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.

State Variation in PSA Screening After the 2011-2012 USPSTF Update

State Variation in PSA Screening After the 2011-2012 USPSTF Update

Not only is there immense state-by-state heterogeneity in PSA screening, but there is also marked variation within each state.

Early Prostate Cancer Salvage ADT Therapy Better

Early Prostate Cancer Salvage ADT Therapy Better

By

Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.

Proximal PSA Predicts Prostate Cancer Metastasis Risk

Proximal PSA Predicts Prostate Cancer Metastasis Risk

By

PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

By

A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.

PSA Testing in Controls of Screening Trial May Undermine Results

PSA Testing in Controls of Screening Trial May Undermine Results

Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Low-PSA, High-Grade Prostate Cancer Especially Lethal

By

Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.

Novel PSA Assay Improves Prostate Cancer Diagnosis

Novel PSA Assay Improves Prostate Cancer Diagnosis

By

The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

By

Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.

More Preclinical PCa, Progression Among Black Men

More Preclinical PCa, Progression Among Black Men

Also increased risk of progression to metastatic disease compared with the general population.

USPSTF Issues Draft PCa Screening Recommendations

USPSTF Issues Draft PCa Screening Recommendations

By

The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.

Earlier vs Later Prostate Cancer Recurrence Characterized

Earlier vs Later Prostate Cancer Recurrence Characterized

By

Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.

Many Men Lack Information on PSA Screening Pros, Cons

Many Men Lack Information on PSA Screening Pros, Cons

By

In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

By

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

By

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

By

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.

New Prostate Cancer Screening Algorithm Proposed

New Prostate Cancer Screening Algorithm Proposed

By

A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.

Radiographic Progression of mCRPC Without Rising PSA

Radiographic Progression of mCRPC Without Rising PSA

By

In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

By

After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.

Digital Rectal Examination, PSA Testing Rates Declining

Digital Rectal Examination, PSA Testing Rates Declining

Decreases in use of screening following USPSTF recommendations against routine PSA screening.

Latest Assays Can Improve Prostate Cancer Workup

Latest Assays Can Improve Prostate Cancer Workup

Clinicians now have tools for improving prostate cancer screening and risk stratification.

PSA of ≥0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

By

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

Sign Up for Free e-newsletters